Activist S.H.N. Sues PRF Technologies in Tel Aviv Court to Force Board Vote
PRFX is trading near its 52-week low of $0.691 (2.9% above the low) on light trading volume (0.1× avg).
Summary
Activist holder S.H.N. petitioned a Tel Aviv court to force PRF Technologies to hold a special meeting on removing most of its board, and to bar the company from issuing securities or appointing directors until then.
Key Events · Corporate Governance and Compliance · PRFX
-
Activist Escalates to Court
On November 2, 2026, S.H.N. Financial Investments filed a petition with the District Court of Tel Aviv (Economic Division) under Section 65 of the Israeli Companies Law seeking an order directing PRF Technologies to convene a special general meeting to vote on removing directors.
-
Issuer Rejected Demand
PRF rejected S.H.N.'s September 24 demand by letters dated October 7 and October 18, 2026, arguing Regulation 7B of the Relief Regulations requires a 10% holding; S.H.N. holds 200,000 shares, or 5.716% of the 3,499,144 shares outstanding as of September 2, 2026.
-
Requested Freeze on Issuances
The petition asks the court to restrict PRF, until the meeting, from actions outside the ordinary course including issuing securities (such as under its agreement with YA II PN, Ltd.) and appointing additional directors, and to award S.H.N. its expenses and attorneys' fees.
-
No Share Transactions
S.H.N., Hadar Shamir and Nir Shamir reported no transactions in PRF securities since the original Schedule 13D filed September 24, 2026.
Analysis · PRFX · Life Sciences
S.H.N. Financial Investments, holding 5.716% of PRF, has taken its fight to remove most of the board from letters to litigation. After PRF rejected the September 24 special-meeting demand — arguing Israeli relief regulations require a 10% stake — S.H.N. filed a petition in Tel Aviv District Court on November 2. The petition asks the court to order a special meeting on removing directors and, critically, to freeze PRF from issuing securities (including under its YA II PN financing arrangement) or adding directors until that meeting happens. For a company that just reported roughly $11.0 million in cash against $2.5 million in liabilities, a court-ordered freeze on capital-raising is the real risk here: it could block the financing flexibility management has been relying on while the governance fight plays out.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.69 to $7.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.